The findings from this study suggest that the earliness at which HIV infection is detected and cART is subsequently initiated is, in combination with HPV vaccination and cervical screening, key to the prevention of cervical cancer in women infected with HIV.
INTRODUCTION
There is a substantial excess of invasive cervical cancer (ICC) among women infected with HIV (WHIV). 1 This excess has tended to be largest in settings where WHIV have access to combined antiretroviral therapy (cART), but are not well reached by cervical screening. [2] [3] [4] Studies have also shown a consistent excess of cervical intraepithelial neoplasia grade 2/3 (CIN2/3) in WHIV. 5, 6 Sexual behaviors that favor acquisition of HIV are the same that favor the acquisition of high-risk human papillomavirus (HPV) types, which leads to a higher prevalence of HPV in WHIV. 7 In addition, however, HIV-related immunodeficiency is known to unfavorably influence HPV natural history. CD4+ cell count is negatively associated with the prevalence, [8] [9] [10] [11] persistence, 12 and cumulative incidence 13 of HPV infection, as well as with cytological abnormalities 11 and CIN2/3 6,14,15 among WHIV.
The effects of HIV-related immunodeficiency on ICC have been more difficult to establish. Firstly, ICC has been classified as an acquired immunodeficiency syndrome (AIDS)-defining cancer since 1993, which created problems for early linkage studies between people with AIDS and cancer registries. Many prevalent cervical cancers diagnosed at AIDS onset had to be excluded from estimations of relative risk. 16 Secondly, screening can substantially curb the ICC burden. 17 Only in recent years are large studies of WHIV revealing that CD4+ cell count is indeed negatively related to ICC risk. [18] [19] [20] The dose response relationship between the level of immunodeficiency and the risk of CIN2/3 and ICC remains unclear, however, as does the effect of cART-induced improvements in immunity on the evolution of cervical neoplasia. Thus, we undertook a case-control study nested within the Swiss HIV Cohort Study (SHCS), a nationwide study of HIV-positive persons, to characterize the influence of immunodeficiency and cART use on the development of CIN2/3 and ICC among WHIV.
MATERIAL AND METHODS

The Swiss HIV Cohort Study
The SHCS is nationwide prospective cohort that has been enrolling HIV-infected persons aged 16 years or older since 1988 from all five Swiss University hospitals (Basel, Bern, Geneva, Lausanne and Zurich), and two cantonal hospitals (St Gallen and Ticino). 21 Since 1995, interested private physicians have also been enrolling patients. Twenty-eight percent of participants in the SHCS are women. The database used for the current study 
Ascertainment of incident cases
Cases of CIN2/3 and of ICC are routinely recorded in the SHCS. Additional cases were identified through record linkage with eight cantonal cancer registries. 22, 23 Prevalent CIN2/3 and ICC cases were defined as women diagnosed before, or within one month of enrolment into the SHCS and were excluded from analyses. 6 
Selection of controls
Three control women never diagnosed with CIN2/3 or ICC were matched to each CIN2/3 or ICC case using incidence density sampling. 24 Controls had at least the same length of follow-up as the matched case, and could serve as controls for only one case.
Matching criteria were: 1) SHCS centre; 2) HIV-transmission category (injecting drug users
[IDU], heterosexual/other); 3) age at enrollment in SHCS (as close as possible, up to a maximum of nine years difference); 4) calendar year of enrollment in SHCS (as close as possible, up to a maximum of nine years difference). For each case a list of possible controls was drawn up and three controls were selected at random.
Definitions
For each case-control pair, the reference date was defined as the date corresponding to the same length of follow-up as the matched case had at the time of the diagnosis of CIN2/3 or ICC (thus cases and controls were also matched for age and year of reference date). The nadir CD4+ cell count was defined as the lowest ever reported CD4+ cell count prior to the reference date.
cART use was defined as a combination of at least three antiretroviral drugs, including a protease inhibitor or a non-nucleoside reverse transcriptase inhibitor or three nucleosides, including abacavir. Only persons who had used cART for more than one month prior to the reference date were classified as ever users, and cART users were additionally stratified by duration of use from date of cART initiation to reference date (≤2 years versus >2 years). This duration may include periods of interruptions, but these occur in only a small fraction of SHCS participants on cART (5-10%). respectively, conditioning on year at reference date meant that most missing data clustered in the same case:control pairs which were effectively dropped from the estimates for these two variables). Chi-square for trend was calculated for the categories listed in the tables. P values of all statistical tests were two-sided.
Median CD4+ cell counts were calculated separately for never and ever cART users in yearly periods prior to the reference date, restricted to cases and controls who (1) were under active follow-up and (2) had a valid CD4+ cell count, in each yearly period. If more than one measurement was available during any one time period, that closest to the reference date was used. Matching was not retained in the presentation of median CD4+ cell counts.
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RESULTS
A total of 508 CIN2/3 and 40 ICC cases were identified in SHCS participants, of whom 437 and 32 were identified from the SHCS database, and 71 and 8 additional cases were identified through record linkage with eight population-based Swiss Cantonal Cancer
Registries. 22, 23 One hundred and forty CIN2/3 and 16 ICC occurring before (or within one month of) SHCS enrollment, as well as four CIN2/3 and four ICC diagnosed more than six months after the last SHCS follow-up date, were excluded, leaving 364 and 20 eligible incident cases occurring during active SHCS follow-up, respectively. Table 1 shows the distribution of the CIN2/3 and ICC cases, as well as their respective controls, by matching variables. For five CIN2/3 cases, only two valid controls were available. A majority of both CIN2/3 and ICC cases were diagnosed after the introduction of cART in 1996 (72% and 65% respectively), and were under active follow-up in the SHCS for less than five years prior to diagnosis (66% and 60%, respectively).
However, ICC cases (mean age 34.3 years) were older than CIN2/3 cases(29.7).
There were no significant associations with history of Pap smear, neither for CIN2/3 nor ICC, but this information was available only for case:control pairs whose reference date was after April 2001 (the date at which this information started to be collected in the SHCS). Nevertheless, findings did suggest frequent lack of screening among ICC cases (37.5%) ( Table 2 ). There was no association of smoking history with CIN2/3 and, although 75% of ICC cases were current or former smokers compared to 51% of controls, this difference did not reach statistical significance. Likewise, no associations with a history of AIDS were observed for either CIN2/3 or ICC ( Table 2) .
Associations of CIN2/3 and ICC with various markers of immunodeficiency are also shown in About half of CIN2/3 and ICC cases had started cART before the reference date (Table 3) , but there were no significant differences in cART use between cases and controls for either disease. Upon stratification by duration of cART use, however, women with ≤2 years use showed elevated CIN2/3 risks compared to never users, whilst those with >2 years use showed non-significantly reduced risks. After additional adjustment for nadir CD4+ cell count, the OR for >2-years cART use was associated with a significant reduction in CIN2/3 risk (OR=0.64, 95% CI: 0.42, 0.98). A similar association, albeit nonsignificant, was seen for ICC risk (e.g. OR for ≥2years versus never=0.34, 95% CI: 0.05, 2.26) ( Table 3) . 
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in ever users (OR for <50 versus ≥350 cells/µL= 6.41, 95% CI: 0.43, 95.1, P for trend=0.26). Figure 1 shows median CD4+ cell counts in yearly periods prior to the reference date in CIN2/3 cases and controls, separately for never and ever cART users. As expected, mean CD4+ cell counts among both cases and controls declined over time among never cART users ( Figure 1A ) but were stable in ever cART users ( Figure 1B ). Median CD4+ cell count was lower in cases compared to that in controls at most time points prior to the reference date, and the size of this difference did not appear to vary by time period, neither for never or ever users. Indeed, the association between CIN2/3 risk and more historical measures of CD4+ count was similar to that for CD4+ cell count at reference date (e.g. 
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DISCUSSION
Our carefully matched case-control study within the SHCS was able to confirm the role of immunodeficiency in the aetiology of CIN2/3 14, 15 and ICC [18] [19] [20] among WHIV.
Furthermore, we showed that increases in CIN2/3 and ICC risk are already evident even at moderate levels of immunosuppression (200-349 cells/µL), similar to our recent findings in the SHCS for anal cancer, which is also HPV-related. 28 Low CD4+ cell counts at diagnosis were significantly associated with risk of CIN2/3, but nadir CD4+ cell count appeared a more discriminant CD4+ measure of both CIN2/3 and ICC.
We were able to demonstrate a protective effect of cART use on the risk of CIN2/3, but exclusively if the use had lasted 2 years or more. Whereas early studies failed to show a significant effect of cART use on HPV-related outcomes, others have since reported significant decreases in prevalence of HPV infection, 15, 29 incidence of cytological lesions, 30 or carcinoma in situ/ICC 4 in medium/long-term users. In our study, the protective effect of cART use on CIN2/3 was strengthened by adjusting for nadir CD4+ cell count, which partially adjusts for the negative confounding of CD4+ cell count by indication to treat.
Indeed, cART tends to be initiated only when CD4+ cell count falls below a certain level, so that non-cART users had higher average nadir CD4+ cell counts than cART users. In our present study, mean nadir CD4+ cell count in cART users was 163 in CIN2/3 and 207 in corresponding controls, versus 293 and 363, respectively among non-cART users.
Previous findings of lack of influence of cART may thus be due to lack of accounting for duration of treatment and CD4+ cell count at cART initiation.
As more than half of cases and controls had never used cART at the reference date, we were able to show the effect of nadir CD4+ cell counts on CIN2/3 both in ever and never users of cART. Two previous studies on this topic showed that CD4+ cell counts at diagnosis were significantly associated with CIN2/3 risk, but in non-cART users only. 14, 15 These findings suggest that cART use can only partially eliminate the negative influence of 
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a low nadir on CIN2/3, which differs from other AIDS-defining malignancies like immunoblastic non-Hodgkin lymphoma 31 and Kaposi sarcoma 32 in which cART can rapidly lower cancer risk. Hence the benefits of cART on ICC may be limited by the nonreversibility of certain pre-invasive stages.
Cervical cancer screening is a pre-requisite for diagnosis of CIN2/3, and its treatment has undoubtedly curbed incidence rates of ICC in the SHCS. Even in the SHCS, however, Our limited data on anti-HPV16 L1 seroprevalence demonstrates the high burden of HPV in SHCS women. Thirty percent of women in the control group were seropositive for anti-HPV16 L1, which compares to only 10% among mixed-sex controls from a large
European-wide population-based study using the same serological assay. 33 Furthermore, whilst anti-HPV16 L1 is considered the best marker of cumulative exposure to HPV16 infection, the reported seroprevalence is certainly an under-estimate as a substantial fraction of HPV infections are known not to elicit L1 seroconversion. 34 Antibodies to HPV16 E6 were seen in ICC, but were almost absent, not only in controls, but also in CIN2/3, confirming them as a marker specific to late stages of HPV malignant transformation in the anogenital tract. 33 Nevertheless, only 15% of ICC cases were seropositive for antibodies against HPV16 E6, which compares to 32% seen in serum samples taken close in time to ICC in the HIV-negative population. 
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An association, albeit non-significant, between smoking and ICC risk in WHIV is consistent with the sexual behavior-adjusted findings from a large pooled analysis of ICC in HIV-uninfected women 36 and with the significant association seen for anal cancer in the SHCS 28 and CIN2/3 in WHIV in the U.S. 6 The SHCS has many strengths, including the duration (predating the introduction of Furthermore, the completeness of recording of CIN2/3 in the SHCS is known to differ over time and between cantons. This is one reason that a nested case:control design with careful matching is probably more appropriate than an incidence rate approach. Although ICC cases were few and gave us limited statistical power to achieve significant associations, previous data are very scant. Indeed, the historically sub-optimal level of cervical screening and treatment in the SHCS meant that the observed rate of ICC was higher than in well-screened cohort studies of WHIV. 6 In conclusion, our data suggest that worsening immunodeficiency, even at only moderately decreased CD4+ cell counts (200-349 CD4+ cells/µL), is a significant risk factor for CIN2/3 and cervical cancer. Thus, the earliness at which HIV infection is 
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Abbreviations: cART, combined antiretroviral therapy; CI, confidence interval; CIN, cervical intra-epithelial neoplasia; ICC, invasive cervical cancer; OR, odds ratio. a conditioned upon matching variables; b conditioned on matching variables and adjusted for nadir CD4 categories in Table 2 .
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